Apply to trial NCT07570862

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Biological intervention

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participants who achieve complete renal response (CRR) at Week 26.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening